Clinical trials: Hypothalamic Diseases
Brain Injuries, Growth Hormone Deficiency
Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury
To establish the effects of genotropin replacement on cognitive function in patients with severe growth hormone deficiency after traumatic brain injury.
- Trial name
- NCT00555009
- Testing
- Genotropin
- Where
- 9 sites in France, Italy and 4 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
Pancreatic Neoplasm, Pituitary Neoplasm
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
- Conditions
- Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
- Trial name
- NCT00958841
- Testing
- pasireotide LAR
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Pituitary Tumor, Pain
Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
A randomized, double-blind, placebo-controlled intervention trial involving 100 treated subjects undergoing endonasal trans-sphenoidal (ENTS) resection of pituitary lesion.
- Trial name
- NCT02351700
- Testing
- IV Caldolor
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Acromegaly
Ultrasound Guided Octreotide LAR Injection in Acromegaly
Approximately half of patients with acromegaly do not respond to treatment with somatostatin receptor ligands such as octreotide LAR.
- Trial name
- NCT00552071
- Testing
- Octreotide LAR 30 MG Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cedars-Sinai Medical Center
Hormone Deficiency, Aging
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly
The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH) on the muscle, bone, and fat tissues of the body.
- Trial name
- NCT01410799
- Testing
- Growth Hormone Releasing Hormone (GHRH )
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
This study will be aimed at investigating the effectiveness of a treatment for brain tumors called Photodynamic Therapy, or PDT.
- Trial name
- NCT01966809
- Testing
- Photofrin photodynamic therapy.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Harry T Whelan, MD
Dwarfism, Growth Hormone Deficiency
Drug Use Investigation of Somatropin for GHD-ADULTS.
Post marketing drug use investigation of Genotropin for GHD-ADULTS.
- Trial name
- NCT00601419
- Testing
- Somatropin
- Volunteers
- 230 people
- Sponsor
- Pfizer
Acromegaly
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland.
- Trial name
- PRIMARYS (NCT00690898)
- Testing
- Lanreotide autogel 120 mg
- Where
- 27 sites in Belgium, Czechia and 7 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
Turner Syndrome, Renal Insufficiency, Chronic
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
- Conditions
- Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
- Trial name
- OPTIMA (NCT00234533)
- Testing
- Somatropin (rDNA origin)
- Where
- 45 sites in Belgium, Czechia and 12 more
- Volunteers
- 251 people
- Sponsor
- Ipsen
Perennial Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
- Trial name
- NCT01133626
- Testing
- Prednisone capsules, Beclomethasone dipropionate
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Acromegaly
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical…
- Trial name
- HOSCAR (NCT01278342)
- Testing
- Sandostatin LAR, pegvisomant, cabergoline
- Where
- 20 sites in France, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Growth Hormone Deficiency
Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial
The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.
- Conditions
- Heart Failure, Growth Hormone Deficiency, Ischemic Heart Disease
- Trial name
- NCT00591760
- Testing
- Somatotropin
- Volunteers
- 56 people
- Sponsor
- Federico II University
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Acromegaly Combination Treatment Study
In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily pegvisomant will attain equivalent control of serum insulin-like growth factor (IGF)-1 levels at a…
- Trial name
- NCT01538966
- Testing
- Pegvisomant, Octreotide LAR, Lanreotide
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Cedars-Sinai Medical Center
Hyperandrogenemia, Polycystic Ovary Syndrome
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Gonadotropin-releasing hormone (GnRH) is a hormone that regulates the ability of the pituitary to secrete two hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
- Trial name
- JCM026 (NCT01428245)
- Testing
- Progesterone, Estrace (estrogen)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Growth Hormone Deficiency
Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin).
- Trial name
- NCT03831880
- Testing
- Genotropin, somatrogon
- Where
- 32 sites in United States, Bulgaria and 3 more
- Volunteers
- 87 people
- Sponsor
- Pfizer
Hypopituitarism, Hypogonadism
Testosterone and Growth Hormone for Bone Loss in Men
Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves.
- Conditions
- Hypopituitarism, Hypogonadism, Growth Hormone Deficiency
- Trial name
- NCT00080483
- Testing
- Testosterone plus somatropin, testosterone
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Pennsylvania
Parkinson's Disease, Hyperprolactinemia
Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
The overall goal of this study will be to assess and monitor the adherence to and effectiveness of the new prescribing guidelines for cabergoline. Specific objectives will be to assess: 1.
- Trial name
- SUCRE (NCT01270711)
- Testing
- Study Drug
- Volunteers
- 22,014 people
- Sponsor
- Pfizer
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis
The purpose of this study is to find out if the Glucagon Stimulation Test (GST) is a reliable alternative to the Insulin Tolerance Test (ITT) for diagnosis of Growth Hormone Deficiency (GHD) and adrenal insufficiency.
- Trial name
- GST (NCT01282164)
- Testing
- Glucagon stimulation test and insulin tolerance test
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic